DNASE1 and hydrops fetalis: Moreover, in the cardiopulmonary bypass (CPB) model, DNase I treatment significantly reduced plasma cfDNA/NETs levels and ameliorated endothelial dysfunction and inflammation, the key complications that contribute to adverse ventricular remodeling and HF risk [188].